Showing 4521-4530 of 6036 results for "".
- Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primateshttps://modernod.com/news/aviceda-announces-successful-completion-of-key-ind-toxicity-milestone-with-favorable-safety-profile-in-non-human-primates/2481280/Aviceda Therapeutics announced completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. Cambridge, Massachusetts-based Aviceda, has developed a proprietary nano-technology HALOS&
- Sifi Launches EpiColin Glaucoma Supplement in Italyhttps://modernod.com/news/sifi-launches-epicolin-glaucoma-supplement-in-italy/2481276/Sifi announced the launch in Italy of EpiColin, a food supplement dedicated to patients suffering from glaucoma. Following Amiriox and Ecbirio, IOP drugs fully reimbursed by the Italian NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by Sifi in th
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e
- NeoLight Launches ROP Risk Management Software ROPCheck.comhttps://modernod.com/news/neolight-launches-rop-risk-management-software-ropcheckcom/2481271/NeoLight announced that it is releasing ROP Check, a software used in digital care coordination for pediatric retinal screening to detect and monitor progression of retinopathy of prematurity (ROP). The launch comes 1 year after NeoLight acquired Phoenix Technology Group, which bro
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- RetinAI Launches Discovery CORE: AI Platform for Retinal Fluid and Layer Segmentationhttps://modernod.com/news/retinai-launches-discovery-core-ai-platform-for-retinal-fluid-and-layer-segmentation/2481269/RetinAI Medical AG has launched Discovery CORE with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and ima
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s
- Meivertor Single-Handed Upper and Lower Eyelid Eversion Tool Now Availablehttps://modernod.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/Introduced at the American Academy of Optometry meeting in San Diego, the Meivertor is designed to be a simple solution for an everyday challenge: eversion of the upper eyelid to image the meibomian glands. "Having images of the meibomian glands is important to
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's